VISEN Pharma Repurchases 6,200 Shares; Treasury Stock Rises to 15,400 Units

Bulletin Express05-19

VISEN Pharmaceuticals announced that on 19 May 2026 it repurchased 6,200 ordinary shares on the Hong Kong Stock Exchange. The transaction represents 0.005 % of the company’s issued share capital (excluding treasury shares) prior to the buyback.

The shares were acquired at prices ranging from HKD 23.00 to HKD 24.56, for a total consideration of HKD 0.15 million. All repurchased shares are being held as treasury stock.

Following the transaction, VISEN Pharma’s issued shares outstanding (excluding treasury shares) decreased to 113.91 million, while total issued shares remained at 113.93 million. The company’s treasury stock position increased from 9,200 to 15,400 shares.

The repurchase falls under a mandate approved on 27 June 2025 that allows VISEN Pharma to buy back up to 11.39 million shares. To date, 15,400 shares, or 0.01352 % of the share count at the mandate date, have been repurchased under this authorization.

Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 18 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169064783?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169064783","market":"us","top_or_hot":-1,"title":"VISEN Pharma Repurchases 6,200 Shares; Treasury Stock Rises to 15,400 Units","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals announced that on 19 May 2026 it repurchased 6,200 ordinary shares on the Hong Kong Stock Exchange. The transaction represents 0.005 % of the company’s issued share capital (excluding treasury shares) prior to the buyback.</p>\n<p>The shares were acquired at prices ranging from HKD 23.00 to HKD 24.56, for a total consideration of HKD 0.15 million. All repurchased shares are being held as treasury stock.</p>\n<p>Following the transaction, VISEN Pharma’s issued shares outstanding (excluding treasury shares) decreased to 113.91 million, while total issued shares remained at 113.93 million. The company’s treasury stock position increased from 9,200 to 15,400 shares.</p>\n<p>The repurchase falls under a mandate approved on 27 June 2025 that allows VISEN Pharma to buy back up to 11.39 million shares. To date, 15,400 shares, or 0.01352 % of the share count at the mandate date, have been repurchased under this authorization.</p>\n<p>Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 18 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Repurchases 6,200 Shares; Treasury Stock Rises to 15,400 Units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Repurchases 6,200 Shares; Treasury Stock Rises to 15,400 Units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-19 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals announced that on 19 May 2026 it repurchased 6,200 ordinary shares on the Hong Kong Stock Exchange. The transaction represents 0.005 % of the company’s issued share capital (excluding treasury shares) prior to the buyback.</p>\n<p>The shares were acquired at prices ranging from HKD 23.00 to HKD 24.56, for a total consideration of HKD 0.15 million. All repurchased shares are being held as treasury stock.</p>\n<p>Following the transaction, VISEN Pharma’s issued shares outstanding (excluding treasury shares) decreased to 113.91 million, while total issued shares remained at 113.93 million. The company’s treasury stock position increased from 9,200 to 15,400 shares.</p>\n<p>The repurchase falls under a mandate approved on 27 June 2025 that allows VISEN Pharma to buy back up to 11.39 million shares. To date, 15,400 shares, or 0.01352 % of the share count at the mandate date, have been repurchased under this authorization.</p>\n<p>Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 18 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1169064783","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169064783","pubTimestamp":1779187405,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals announced that on 19 May 2026 it repurchased 6,200 ordinary shares on the Hong Kong Stock Exchange. The transaction represents 0.005 % of the company’s issued share capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"维森制药回购6200股；库存增至15,400股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals announced that on 19 May 2026 it repurchased 6,200 ordinary shares on the Hong Kong Stock Exchange. The transaction represents 0.005 % of the company’s issued share capital (excluding treasury shares) prior to the buyback.\nThe shares were acquired at prices ranging from HKD 23.00 to HKD 24.56, for a total consideration of HKD 0.15 million. All repurchased shares are being held as treasury stock.\nFollowing the transaction, VISEN Pharma’s issued shares outstanding (excluding treasury shares) decreased to 113.91 million, while total issued shares remained at 113.93 million. The company’s treasury stock position increased from 9,200 to 15,400 shares.\nThe repurchase falls under a mandate approved on 27 June 2025 that allows VISEN Pharma to buy back up to 11.39 million shares. To date, 15,400 shares, or 0.01352 % of the share count at the mandate date, have been repurchased under this authorization.\nUnder Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 18 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169064783","isCrawlerRequest":true}